FDA Progesterone on HVD vs Endrenyi [RSABE / ABEL]

posted by FI – Austria, 2012-03-09 14:50 (5225 d 21:09 ago) – Posting: # 8244
Views: 13,137

Dear all,

I cross-checked the L. Endrenyi/L Tothfalusi chapter in Kanfer/Shargel’s book “Generic Drug Product Development” and found a difference to the code provided by FDA for Progesterone:
The so called “x” (=PE²-SE²) in the Progesterone BE recommendation does not resemble the Em (=PE²) which would be necessary to have the identical formula for the Confidence limit calculation:

CL = Em-Es + √(Lm+Ls) acc. to your Kanfer/Shargel Chapter

I tried now to simulate data in EXCEL to find out, which one is correct and calculated a “third” way of concluding BE: simply the exponentiated CI for the difference of the means using the SE of the differences.

Instead of solving the problem, I have now 3 (slightly) differing results; This might be due to simple programming mistake but I couldn’t find them up to now;

1) Does anyone know, if there is a(nother) mistake in the FDA recommendation (the “x” as described above)?

Thanks a lot


Edit: Category changed. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
267 visitors (0 registered, 267 guests [including 30 identified bots]).
Forum time: 13:00 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5